**Name of Journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 67003

**Manuscript Type:** MINIREVIEWS

**New horizons for uncommon mutations in non-small cell lung cancer: *BRAF*, *KRAS*, *RET*, *MET*, *NTRK*, *HER2***

Olmedo ME *et al*. New horizons for NSCLC uncommon mutations

Maria Eugenia Olmedo, Raquel Cervera, Luis Cabezon-Gutierrez, Yolanda Lage, Elena Corral de la Fuente, Ana Gómez Rueda, Xabier Mielgo-Rubio, Juan Carlos Trujillo, Felipe Couñago

**Maria Eugenia Olmedo, Yolanda Lage, Ana Gómez Rueda,** Department of Medical Oncology, Ramón y Cajal University Hospital, Madrid 28034, Spain

**Raquel Cervera,** Department of Medical Oncology, Del Henares University Hospital, Coslada 28822, Madrid, Spain

**Luis Cabezon-Gutierrez,** Medical Oncology, Hospital Universitario de Torrejón, Torrejón de Ardoz 28850, Madrid, Spain

**Elena Corral de la Fuente,** Medical Oncology Department, Hospital Universitario Ramon y Cajal, Madrid 28034, Spain

**Xabier Mielgo-Rubio,** Department of Medical Oncology, Foundation Alcorcón University Hospital, Alcorcón 28922, Madrid, Spain

**Juan Carlos Trujillo,** Department Thoracic Surgery, Hospital de la Santa Creu I Sant Pau, Barcelona 08029, Catalonia, Spain

**Juan Carlos Trujillo,** Department of Surgery, Universitat Autonoma de Barcelona, Barcelona 08029, Catalonia, Spain

**Felipe Couñago,** Department of Radiation Oncology, Hospital Universitario Quirónsalud Madrid, Pozuelo 28223, Madrid, Spain

**Felipe Couñago,** Department of Radiation Oncology, Hospital La Luz, Madrid 28003, Spain

**Felipe Couñago,** Medicine Department, School of Biomedical Sciences, Universidad Europea de Madrid, Madrid 28670, Spain

**Author contributions:** Olmedo ME, Cervera R, Cabezón L, Lage Y, Corral de la Fuente E, Gómez Rueda Aperformed research and wrote the paper; Couñago F, Trujillo JC, Mielgo-Rubio X contributed a critical review of the manuscript for important intellectual content; Mielgo-Rubio X contributed to management of the manuscript and submission.

**Corresponding author: Maria Eugenia Olmedo, MD, PhD, Consultant Physician-Scientist,** Department of Medical Oncology, Ramón y Cajal University Hospital, M-607, km. 9, 100, Madrid 28034, Spain. maruolmedogarcia@hotmail.com

**Received:** April 19, 2021

**Revised:** September 5, 2021

**Accepted: April 3, 2022**

**Published online:**

**Abstract**

The 2004 discovery of *EGFR* mutations, followed by *ALK* rearrangements, ushered in a targeted therapy era for advanced non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors targeting gene alterations have substantially improved survival and quality of life for patients with NSCLC. In the last decade, rearrangements of the ROS1 oncogene have been incorporated into healthcare practice that are applicable to another small subgroup of patients who benefit from similar targeted strategies. Recent genome studies of lung adenocarcinoma have identified other possible therapeutic targets, including *RET*, *NTRK* fusions, *c-MET* alterations, and activating mutations in *KRAS*, *BRAF*, and *HER2,* all with frequencies greater than 1%. Lung cancers harbouring these genome changes can potentially be treated with agents approved for other indications or under clinical development. This review updates the therapeutic arsenal that especially targets those genes.

**Key Words:** *BRAF*; *NTRK*; *KRAS*; *MET*; *RET*; *HER2*; Non-small cell lung cancer; Targeted therapy; Uncommon mutations

Olmedo ME, Cervera R, Cabezon-Gutierrez L, Lage Y, Corral de la Fuente E, Gómez Rueda A, Mielgo-Rubio X, Trujillo JC, Couñago F. New horizons for uncommon mutations in non-small cell lung cancer: *BRAF*, *KRAS*, *RET*, *MET*, *NTRK*, *HER2*. *World J Clin Oncol* 2022; In press

**Core Tip:** Compared to other types of cancer, non-small cell lung cancer (NSCLC) is highly genetically altered. Outside of *EGFR, ALK,* and *ROS1*, reflecting 15%-20% of clinical practice, other molecular alterations with important recent advances in their therapeutic arsenal and already in phase II/III trials are *BRAF, KRAS, RET, MET, NTRK,* and *HER2*. The goal is to achieve, compared to conventional treatments such as chemotherapy, better symptom control, better response rates, and improved progression-free survival and overall survival in patients with NSCLC.

**INTRODUCTION**

Approximately 60% of lung adenocarcinomas harbour molecular alterations in driver oncogenes, with incidence, which varies according to ethnic origin and alteration, as follows: epidermal growth factor receptor (EGFR)mutation, 15%-20%[1];anaplastic lymphoma kinase (*ALK*) rearrangement, 5%-7%[2];and c-ros 1 (*ROS1*) rearrangement, approximately 1%[3].There has been an impressive improvement in survival in response to tyrosine kinase inhibitors (TKIs), which also have a better toxicity profile compared to standard chemotherapy.

The consequent improvement in molecular understanding of non-small cell lung carcinoma (NSCLC) has allowed increasingly exhaustive molecular classification as well as identification of a subset of patients susceptible to specifically targeted therapy. The outcome of massive gene-sequencing platforms with higher throughput than gene-to-gene determinations is that patients can be offered more treatments that more specifically impact on their quality of life and survival. The current recommendation is to carry out a comprehensive molecular analysis using multiplex platforms – next-generation sequencing (NGS) – if available, considering advantages in terms of coverage, time, and a favorable economic profile[4]. NGS is capable of detecting less common or difficult-to-identify oncogenes, such as Kirsten rat sarcoma viral oncogene homolog (*KRAS*) mutations (30%-35%), V-raf murine sarcoma viral oncogene homolog B (*BRAF*) mutations (4%-5%), mesenchymal-epithelial transition factor (*c-MET*) alterations, exon 14 insertions and/or amplifications (5%-9%), rearrangements during transfection (*RET*) (1%-2%), human epidermal growth factor receptor 2 (*HER2*) mutations (2%), and neurotrophic receptor tyrosine kinase (*NTRK*) fusions (< 1%)[5]. Identifying these alterations is increasingly important, as new specific drugs in clinical development show promise in terms of modifying the natural history of NSCLC. We focus on direct inhibitors of pathways and their practice-changing results.

***BRAF***

Present in 2%-3% of NSCLC cases, the *BRAF* mutation is mostly encountered in patients diagnosed with adenocarcinoma[6].The most commonvariant is *V600E*, found in 50%-60% of patients with *BRAF*-mutated (*BRAF*m) NSCLC. Not clear is the prognostic value of *BRAF-V600E*compared with non-*V600E* or with the rest of patients with NSCLC[7].

The drugs used to date for this molecular alteration are the same TKIs that have proven to be effective in treating melanoma, a tumour with high *BRAF*m frequency.

Table 1 summarizes the efficacy of the main drugs used to date. The best results have been reported for dabrafenib combined with trametinib, which attempt to block the MAPK pathway at two different sites (*BRAF*and *MEK*), thus overcoming possible tumour resistance to TKIs. The BRF113928 study in patients who received 2-4 Lines of therapy reported an objective response rate (ORR) of 63.2%, and a first-line ORR of 64%[8-12].

However, the absence of comparative data for first and subsequent lines of therapy as currently used for this group of patients means that it is not possible to confirm significant clinical benefit and efficacy over alternative therapies. Dabrafenib and trametinib may therefore be of use for patients for whom standard therapies are not possible or have failed.

Phase II studies are also currently recruiting for the encorafenib + binimetinib (NCT04526782) and cobimetinib + vemurafenib (NCT03178552) combinations.

***KRAS***

*KRAS* is the most common mutation in NSCLC, present in up to 30% of adenocarcinomas[13].In 80% of cases it is located at codon 12, and the most frequent mutation is *KRAS-G12C*, reflected in 13% of all lung adenocarcinomas. It is considered practically exclusive in relation to any other clinical practice drivers, although co-occurrences have been found with alterations in *TP53*, cyclin dependent kinase inhibitor 2A/B (*CDKN2A/B*), *STK11*, and *KEAP1 (*Kelch Like ECH Associated Protein 1)[14].

While *KRAS*has been a therapeutic target for decades, no direct therapeutic option has been established. In recent years, new direct inhibitors of *KRAS-G12C*have emerged. Phase II trial results for sotorasib, an irreversible and highly selective *KRAS-G12C* inhibitor, have positioned it as a major lung cancer milestone for the *KRAS* mutation[15,16];for 126 included patients, the ORR was 37.1%, there were three complete responses (CRs) and 43 partial responses (PRs), and the disease control rate was 80.6%, for a median progression-free survival (PFS) of 6.8 mo and a good tolerability profile. Based on those data, an application for marketing authorization has been submitted to the FDA and EMA.

In two presentations at the 32nd Symposium on Cancer Therapeutics and Molecular Targets EORTC-NCI-AACR[17,18], investigators from the KRYSTAL-1 phase I and II clinical trial reported that adagrasib clinical activity has been demonstrated in previously treated patients with NSCLC and the *KRAS-G12C*mutation. Promising preliminary data for this drug are to be further evaluated in trials, along with combinations, including with pembrolizumab in the KRYSTAL-7 phase 2 trial (NCT04613596) of untreated patients[19].

***RET***

*RET* gene fusions and activating point mutations are primary oncogenic drivers that are usually mutually exclusive with other oncogenic driver alterations[20]. Among the various oncogene drivers in NSCLC, the *RET* gene is involved in various chromosomal rearrangements, found in 1%-2% of all NSCLC patients[21].

Most of the drugs active against *RET* are TKIs. Multikinase inhibitors initially studied in phase II clinical trials include cabozantinib, nintedanib, lenvatinib, vandetanib, and sorafenib, each with a different ORR (Table 2)[22-25].

Selpercatinib (LOXO-292) is a highly selective, potent, central nervous system (CNS)-active, small-molecule *RET* kinase inhibitor. Selpercatinib has nanomolar potency against wild-type *RET* and other *RET* alterations, including the *KIF5B-RET* fusion and *V804M* gatekeeper mutation, in both enzyme and cellular assays, with minimal activity against other kinase and non-kinase targets[26].

In the LIBRETTO-001 phase I/II trial, selpercatinib treatment demonstrated clinically meaningful responses and sustained antitumour activity, for a manageable toxicity profile, in both heavily pre-treated and treatment-naive patients, and including patients with brain metastases and with *RET* fusion-positive NSCLC (intracranial CNS (*n* = 10/11): ORR 91%). In May 2020, selpercatinib was approved by the FDA under the Accelerated Approval programme for the treatment of *RET*-altered cancers (NSCLC and thyroid cancer)[27].

Pralsetinib (BLU-667) is a novel small-molecule *RET* inhibitor, designed for high potency and selectivity against oncogenic *RET* alterations, including the most frequent *RET*rearrangements (*e.g.*, *KIF5B–RET* and *CCDC6–RET*). The global phase I/II ARROW study has demonstrated broad and durable antitumour activity for pralsetinib in a variety of advanced *RET*-altered solid tumours, including *RET* fusion+ NSCLC. For 354 patients with advanced solid tumours who received pralsetinib as first-line treatment, the ORR was 73%, for a 12% CR rate (*n* = 26). Treatment-related adverse events were most frequently grade 1-2[28]. Table 2 summarizes the activity of the different TKIs against *RET*.

RXDX-105 differs from the other multi-targeted TKIs because it has *RET* activity but limited activity against the vascular endothelial growth factor (*VEGF*) receptors. In *RET* TKI-naive patients, the drug showed modest activity. Subset analysis revealed that the ORR varied by fusion partner. ORRs were 0% (0/20) in the *RET-KIF5B* rearrangement subset (the most common rearrangement) and 67% (6/9) in the *RET*-non-*KIF5B* rearrangement subset[29].

***MET***

*c-MET* is an oncogene that encodes a tyrosine kinase receptor whose ligand is hepatocyte growth factor (*HGF*). Alterations in *c-MET* (mutation, amplification, or overexpression) cause abnormal receptor activity that is associated with rapid tumour growth, greater tumour aggressiveness, and resistance to cancer treatments[30].

*c-MET* amplification is present in 1%-6% of patients with NSCLC. Skipping mutation of exon 14 occurs in 3%-4% of cases, most frequently for non-squamous and sarcomatoid histologies (20%-30%). This alteration occurs most frequently in older patients and in smokers.

Selective and non-selective *c-MET*inhibitors (Tables 3 and 4) are currently available that can impact on survival in patients with NSCLC. The first drug to demonstrate efficacy with this tumour subtype was crizotinib: in the PROFILE 1001 study, the ORR was 32% and PFS was 7.3 mo[31].

Capmatinib is another drug that has been shown to be active: in the GEOMETRY MONO-1 study, the ORR was 41% and PFS was 5.4 mo in previously treated patients; in first-line patients, the ORR was 68% and PFS was 12.4 mo, while ORR was 54% for intracranial activity[32].In the VISION study, tepotinib achieved an ORR greater than 40%, irrespective of the therapy line, PFS of 8.5 mo, and an ORR of 55% for intracranial activity[33].Regarding *MET* amplification, TKIs have only significantly benefited tumours with a high level of amplification (*MET/CEP7* > 5), for an ORR of 40% with crizotinib and of 47% with capmatinib.

Amplification, which may appear de novo or as a mechanism of resistance to the targeted treatment of *EGFR* tumours, is present in 4% of cases of progression to first/second generation inhibitors, and in 15% of cases of progression to osimertinib. Being explored, therefore, is the combination of *EGFR* inhibitors and *MET* inhibitors.

The TATTON study explored osimertinib combined with savolitinib in patients with NSCLC and mutated *EGFR*. In the group that received initial treatment with a first/second generation inhibitor, the ORR was 52%, while in the group that received osimertinib, the ORR was 25%, for an acceptable toxicity profile[34].

As for immunotherapy, despite the fact that the tumours may present with elevated *PD-L1*expression, the benefit reported for retrospective studies by a French group was limited, at an ORR of 16% and PFS of 3.4 mo[35].

***NTRK***

The tropomyosin receptor kinase (*TRK*) family consists of three tyrosine kinase receptors – *TRKA, TRKB,*and *TRKC* isoforms, encoded by the *NTRK1, NTRK2,*and*NTRK3*genes, respectively – that are mainly expressed in the nervous system. Their fusions involve some 80 associated genes and they are known oncogenic drivers[35-38].The incidence of *NTRK* fusions in NSCLC is estimated to be 0.1%-0.2%, affecting a population that is unselected in terms of sex, age, or smoking[37].

Currently, two first-generation TKIs targeting *NTRK*fusions have been approved by the FDA and the EMA: entrectinib (multikinase *ALK, ROS1,*and pan-*TRK* inhibitor) and larotrectinib (selective pan-*TRK*inhibitor). Both have demonstrated great efficacy (irrespective of histology or fusion gene) and intracranial activity, as well as good toxicity profiles[38-41].

Larotrectinib efficacy and safety in patients with solid tumours and *NTRK*fusions have been evaluated in two registrational phase I/II studies (NCT02122913 and NCT02576431). By July 2020, 20 patients with TRK fusion-positive lung cancer had been treated. Joint analysis of those studies, yielded an ORR of 73% and a CR rate of 7% for patients with lung cancer. The median PFS and OS in lung cancer patients was 35.4 and 40.7 mo. Among patients with baseline central nervous system metastases, the ORR was 63%. Reported adverse events were mostly grade 1-2[38].

Entrectinib was evaluated in the phase I ALKA-372-001 trial, phase I STARTRK-1 trial and phase II STARTRK-2 basket trial. For the 10 patients with NSCLC, the ORR was 70%, the CR rate was 10%, and PFS was 14.9 mo. Entrectinib showed a good toxicity profile; most adverse events were grade 1 or 2 and reversible, *e.g.*, dysgeusia, constipation, fatigue, diarrhoea, oedema, and dizziness[39].

Selitrectinib (LOXO 195), repotrectinib (TPX-0005), and taletrectinib (DS-6051b/AB-106) are second-generation drugs capable of inhibiting on-target resistance of *NTRK*[37,40]*.* They are currently being evaluated in phase I/II clinical trials in patients with *NTRK*-positive tumours who have progressed to first-generation inhibitors (NCT03215511, EudraCT 2017-004246-20, NCT04094610, TRIDENT-1: NCT03093116, NCT02279433).

***HER2***

*HER2* is a cell growth promoting protein, a member of the *ERBB*family of tyrosine kinase receptors expressed on the surface of many types of tumours.

Overexpression, which occurs in 2%-20% of cases depending on the immunohistochemistry (IHC) level (IHC2+/3+), is associated with a poor prognosis. *HER2* amplification occurs, especially in adenocarcinomas, in around 3% of cases without prior treatment and in approximately 10% of cases of *EGFR* resistance to TKIs[42].

*HER2* mutations *(HER2*m*)* – usually consisting of insertions in exon 20, especially in codon 776 – appear mainly in women, in adenocarcinoma cases, and in the Asian population, and never in smokers. The insertions cause constitutive activation of the receptor, making it sensitive to dual TKI action against *EGFR*and *HER2*, but not exclusively to *EGFR*inhibition[43].

The therapies commonly used to target *HER2* in breast cancer have not had the same results for NSCLC. The emergence of new TKIs and conjugated antibodies have given a new boost to therapies for this molecular alteration in NSCLC (Table 5). Reported for the largest retrospective EUHER2 study, which included patients with *HER2* exon 20 insertions, was an ORR of 7.4% for treatment with the TKIs afatinib, lapatinib, and neratinib; for the trastuzumab antibody and the trastuzumab emtansine (T-DM1) antibody-drug conjugate, the ORR was a more effective 50.9%, but that treatment was in most cases combined with chemotherapy[44,45].

Two phase II studies, of neratinib combined with trastuzumab in *HER2*m patients in first or successive therapy lines (NCT01953926) and of neratinib with temsirolimus (NCT01827267), have reported ORRs of 17% and 19%, respectively[46].Zhou *et al*[47] explored the efficacy of pyrotinib in monotherapy, reporting an ORR of 30%, median PFS of 6.9 mo, and overall survival (OS) of 14.4 mo; the main toxicity, as with other *HER2*-targeting TKIs such as neratinib and lapatinib, was diarrhoea. In the phase II ZENITH20 trial of poziotinib, another pan-*HER*TKI, for the *HER2*m treatment the ORR was 28%, PFS was 5.5 mo, and the toxicity profile was similar to that for pyrotinib[48].

In addition to the *HER2*TKIs, also being evaluated in this setting are antibody-drug conjugates such as T-DM1 and trastuzumab deruxtecan (DS-8201, T-Dxd). Peters *et al*[49]. explored responses to TDM-1 in 49 patients with IHC2+/3+ overexpression, reporting no response for the IHC2+ cohort and 4 PRs for the IHC3+ cohort (20%).Better data is available for trastuzumab deruxtecan. For 42 patients with *HER2*m in the DESTINY-Lung01 cohort, the ORR was 62%, PFS was 14 mo; median OS was not achieved, while OS was 24.5% in the IHC2+/3+ overexpression cohorts[50].

To confirm the PFS benefit, a phase III trial of pyrotinib *vs* docetaxel called PYRAMID-1 (NCT04447118) is ongoing.

**CONCLUSION**

Compared to traditional chemotherapy, the improved TKI targeting of *EGFR* mutations and *ALK/ROS1*translocations has led to significant efficacy and quality of life improvements in the management of patients with NSCLC.  While this subgroup of patients inevitably develops resistance to TKIs, this can be overcome by developing new next-generation TKIs or drugs aimed at overcoming resistance from the outset or from the time of discovery[51,52].

These developments may also be transferable to the treatment of patients with other molecular alterations of *BRAF, KRAS, RET, MET, NTRK* and *HER2.* As can be seen above, a growing number of drugs and combinations are becoming available that target these alterations, often producing a significant improvement in response and survival rates.

Given the many common and rare molecular alterations in NSCLC, full-panel multigene NGS is recommended rather than gene-by-gene sequencing, as not only is it more cost-effective, it allows patients with a target to be easily identified and treated, whether with an approved drug or in a clinical trial of a promising drug[53-55].

**REFERENCES**

1 **Papadimitrakopoulou VA**, Mok TS, Han JY, Ahn MJ, Delmonte A, Ramalingam SS, Kim SW, Shepherd FA, Laskin J, He Y, Akamatsu H, Theelen WSME, Su WC, John T, Sebastian M, Mann H, Miranda M, Laus G, Rukazenkov Y, Wu YL. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. *Ann Oncol* 2020; **31**: 1536-1544 [PMID: 32861806 DOI: 10.1016/j.annonc.2020.08.2100]

2 **Shaw AT**, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med* 2013; **368**: 2385-2394 [PMID: 23724913 DOI: 10.1056/NEJMoa1214886]

3 **Kalemkerian GP**, Narula N, Kennedy EB, Biermann WA, Donington J, Leighl NB, Lew M, Pantelas J, Ramalingam SS, Reck M, Saqi A, Simoff M, Singh N, Sundaram B. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. *J Clin Oncol* 2018; **36**: 911-919 [PMID: 29401004 DOI: 10.1200/JCO.2017.76.7293]

4 **Shaw AT**, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. *Ann Oncol* 2019; **30**: 1121-1126 [PMID: 30980071 DOI: 10.1093/annonc/mdz131]

5 **Ekman S**. How selecting best therapy for metastatic *NTRK* fusion-positive non-small cell lung cancer? *Transl Lung Cancer Res* 2020; **9**: 2535-2544 [PMID: 33489816 DOI: 10.21037%2Ftlcr-20-434]

6 **Chen D**, Zhang LQ, Huang JF, Liu K, Chuai ZR, Yang Z, Wang YX, Shi DC, Liu Q, Huang Q, Fu WL. BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis. *PLoS One* 2014; **9**: e101354 [PMID: 24979348 DOI: 10.1371/journal.pone.0101354]

7 **Couraud S**, Barlesi F, Fontaine-Deraluelle C, Debieuvre D, Merlio JP, Moreau L, Beau-Faller M, Veillon R, Mosser J, Al Freijat F, Bringuier PP, Léna H, Ouafik L, Westeel V, Morel A, Audigier-Valette C, Missy P, Langlais A, Morin F, Souquet PJ, Planchard D; Biomarkers France Contributors. Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study. *Eur J Cancer* 2019; **116**: 86-97 [PMID: 31181537 DOI: 10.1016/j.ejca.2019.04.016]

8 **Subbiah V**, Gervais R, Riely G, Hollebecque A, Blay JY, Felip E, Schuler M, Gonçalves A, Italiano A, Keedy V, Chau I, Puzanov I, Raje NS, Meric-Bernstam F, Makrutzki M, Riehl T, Pitcher B, Baselga J, Hyman DM. Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With *BRAF* V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. *JCO Precis Oncol* 2019; **3**: 1-9 [PMID: 32914022 DOI: 10.1200/PO.18.00266]

9 **Mazieres J**, Cropet C, Montané L, Barlesi F, Souquet PJ, Quantin X, Dubos-Arvis C, Otto J, Favier L, Avrillon V, Cadranel J, Moro-Sibilot D, Monnet I, Westeel V, Le Treut J, Brain E, Trédaniel J, Jaffro M, Collot S, Ferretti GR, Tiffon C, Mahier-Ait Oukhatar C, Blay JY. Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations. *Ann Oncol* 2020; **31**: 289-294 [PMID: 31959346 DOI: 10.1016/j.annonc.2019.10.022]

10 **Planchard D**, Kim TM, Mazieres J, Quoix E, Riely G, Barlesi F, Souquet PJ, Smit EF, Groen HJ, Kelly RJ, Cho BC, Socinski MA, Pandite L, Nase C, Ma B, D'Amelio A Jr, Mookerjee B, Curtis CM Jr, Johnson BE. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. *Lancet Oncol* 2016; **17**: 642-650 [PMID: 27080216 DOI: 10.1016/S1470-2045(16)00077-2]

11 **Planchard D**, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. *Lancet Oncol* 2016; **17**: 984-993 [PMID: 27283860 DOI: 10.1016/S1470-2045(16)30146-2]

12 **Planchard D**, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. *Lancet Oncol* 2017; **18**: 1307-1316 [PMID: 28919011 DOI: 10.1016/S1470-2045(17)30679-4]

13 **Veluswamy R**, Mack PC, Houldsworth J, Elkhouly E, Hirsch FR. KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing. *J Mol Diagn* 2021; **23**: 507-520 [PMID: 33618059 DOI: 10.1016/j.jmoldx.2021.02.002]

14 **Arbour KC**, Jordan E, Kim HR, Dienstag J, Yu HA, Sanchez-Vega F, Lito P, Berger M, Solit DB, Hellmann M, Kris MG, Rudin CM, Ni A, Arcila M, Ladanyi M, Riely GJ. Effects of Co-occurring Genomic Alterations on Outcomes in Patients with *KRAS*-Mutant Non-Small Cell Lung Cancer. *Clin Cancer Res* 2018; **24**: 334-340 [PMID: 29089357 DOI: 10.1158/1078-0432.CCR-17-1841]

15 **Hong DS**, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. *N Engl J Med* 2020; **383**: 1207-1217 [PMID: 32955176 DOI: 10.1056/NEJMoa1917239]

16 **Li BT**. CodeBreaK 100: Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutated Non-small Cell Lung Cancer. IASLC 2021; Abstract PS01.07

17 **Jänne PA**, Rybkin II, Spira AI, Riely GJ, Papadopoulos KP, Sabari JK, Johnson ML, Heist RS, Bazhenova L, Barve M, Pacheco JM, Leal TA, Velastegui K, Cornelius C, Olson P, Christensen JG, Kheoh T, Chao RC, Ou SHI. KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation. *Eur J Cancer* 2020; **138**: S1-S2 [DOI: 10.1016/s0959-8049(20)31076-5]

18 **Johnson ML**, Ou SHI, Barve M, Rybkin II, Papadopoulos KP, Leal TA, Velastegui Karen, Christensen JG, Kheoh T, Chao RC, Weiss J. KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients With Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRASG12C Mutation. *Eur J Cancer* 2020; **138**: S2 [DOI: 10.1016/S0959-8049(20)31077-7]

19 **Mirati Therapeutics Inc**. Phase 2 trial of MRTX849 plus pembrolizumab for NSCLC with KRAS C12C mutation KRYSTAL-7. ClinicalTrials.gov. Acailable from: <https://clinicaltrials.gov/ct2/show/NCT04613596>

20 **Bronte G**, Ulivi P, Verlicchi A, Cravero P, Delmonte A, Crinò L. Targeting RET-rearranged non-small-cell lung cancer: future prospects. *Lung Cancer (Auckl)* 2019; **10**: 27-36 [PMID: 30962732 DOI: 10.2147/LCTT.S192830]

21 **Cancer Genome Atlas Research Network**. Comprehensive molecular profiling of lung adenocarcinoma. *Nature* 2014; **511**: 543-550 [PMID: 25079552 DOI: 10.1038/nature13385]

22 **Drilon A**, Rekhtman N, Arcila M, Wang L, Ni A, Albano M, Van Voorthuysen M, Somwar R, Smith RS, Montecalvo J, Plodkowski A, Ginsberg MS, Riely GJ, Rudin CM, Ladanyi M, Kris MG. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. *Lancet Oncol* 2016; **17**: 1653-1660 [PMID: 27825636 DOI: 10.1016/S1470-2045(16)30562-9]

23 **Lee SH**, Lee JK, Ahn MJ, Kim DW, Sun JM, Keam B, Kim TM, Heo DS, Ahn JS, Choi YL, Min HS, Jeon YK, Park K. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial. *Ann Oncol* 2017; **28**: 292-297 [PMID: 27803005 DOI: 10.1093/annonc/mdw559]

24 **Hida T**, Velcheti V, Reckamp KL, Nokihara H, Sachdev P, Kubota T, Nakada T, Dutcus CE, Ren M, Tamura T. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma. *Lung Cancer* 2019; **138**: 124-130 [PMID: 31710864 DOI: 10.1016/j.lungcan.2019.09.011]

25 **Horiike A**, Takeuchi K, Uenami T, Kawano Y, Tanimoto A, Kaburaki K, Tambo Y, Kudo K, Yanagitani N, Ohyanagi F, Motoi N, Ishikawa Y, Horai T, Nishio M. Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer. *Lung Cancer* 2016; **93**: 43-46 [PMID: 26898613 DOI: 10.1016/j.lungcan.2015.12.011]

26 **Subbiah V**, Velcheti V, Tuch BB, Ebata K, Busaidy NL, Cabanillas ME, Wirth LJ, Stock S, Smith S, Lauriault V, Corsi-Travali S, Henry D, Burkard M, Hamor R, Bouhana K, Winski S, Wallace RD, Hartley D, Rhodes S, Reddy M, Brandhuber BJ, Andrews S, Rothenberg SM, Drilon A. Selective RET kinase inhibition for patients with RET-altered cancers. *Ann Oncol* 2018; **29**: 1869-1876 [PMID: 29912274 DOI: 10.1093/annonc/mdy137]

27 **Drilon A**, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. Efficacy of Selpercatinib in *RET* Fusion-Positive Non-Small-Cell Lung Cancer. *N Engl J Med* 2020; **383**: 813-824 [PMID: 32846060 DOI: 10.1056/NEJMoa2005653]

28 **ainor JF,** Curigliano G, Kim DW, Ho Lee D, Besse B, Baik CS, *et al* Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC). J Clin Oncol 38: 2020 (suppl; abstr 9515)

29 **Drilon A**, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC, Wozniak A, Reckamp KL, Seery T, Nikolinakos P, Hu Z, Oliver JW, Trone D, McArthur K, Patel R, Multani PS, Ahn MJ. A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. *Cancer Discov* 2019; 9: 384-395 [PMID: 30487236 DOI: 10.1158/2159-8290.CD-18-0839]

30 **Salgia R**, Sattler M, Scheele J, Stroh C, Felip E. The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. *Cancer Treat Rev* 2020; 87: 102022 [PMID: 32334240 DOI: 10.1016/j.ctrv.2020.102022]

31 **Drilon A**, Clark JW, Weiss J, Ou SI, Camidge DR, Solomon BJ, Otterson GA, Villaruz LC, Riely GJ, Heist RS, Awad MM, Shapiro GI, Satouchi M, Hida T, Hayashi H, Murphy DA, Wang SC, Li S, Usari T, Wilner KD, Paik PK. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. *Nat Med* 2020; 26: 47-51 [PMID: 31932802 DOI: 10.1038/s41591-019-0716-8]

32 **Wolf J**, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Capmatinib in *MET* Exon 14-Mutated or *MET*-Amplified Non-Small-Cell Lung Cancer. *N Engl J Med* 2020; **383**: 944-957 [PMID: 32877583 DOI: 10.1056/NEJMoa2002787]

33 **Paik PK**, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Tepotinib in Non-Small-Cell Lung Cancer with *MET* Exon 14 Skipping Mutations. *N Engl J Med* 2020; **383**: 931-943 [PMID: 32469185 DOI: 10.1056/NEJMoa2004407]

34 **Sequist LV**, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, Yang JC, Lee JS, Su WC, Kowalski D, Orlov S, Cantarini M, Verheijen RB, Mellemgaard A, Ottesen L, Frewer P, Ou X, Oxnard G. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. *Lancet Oncol* 2020; **21**: 373-386 [PMID: 32027846 DOI: 10.1016/S1470-2045(19)30785-5]

35 **Mazieres J**, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van den Heuvel M, Neal J, Peled N, Früh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez-Marti A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. *Ann Oncol* 2019; **30**: 1321-1328 [PMID: 31125062 DOI: 10.1093/annonc/mdz167]

36 **Cocco E**, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. *Nat Rev Clin Oncol* 2018; **15**: 731-747 [PMID: 30333516 DOI: 10.1038/s41571-018-0113-0]

37 **Amatu A**, Sartore-Bianchi A, Bencardino K, Pizzutilo EG, Tosi F, Siena S. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. *Ann Oncol* 2019; **30**: viii5-viii15 [PMID: 31738427 DOI: 10.1093/annonc/mdz383]

38 **Drilon A**, Tan DSW, Lassen UN, Leyvraz S, Liu Y, Patel JD, Rosen L, Solomon B, Norenberg R, Dima L, Brega N, Shen L, Moreno V, Kummar S, Lin JJ. Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers. *JCO Precis Oncol* 2022; **6**: e2100418 [PMID: 35085007 DOI: 10.1200/PO.21.00418]

39 **Garrido P**, Hladun R, de Álava E, Álvarez R, Bautista F, López-Ríos F, Colomer R, Rojo F. Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours. *Clin Transl Oncol* 2021; **23**: 1529-1541 [PMID: 33620682]

40 **Hong DS**, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, van Tilburg CM, Nagasubramanian R, Berlin JD, Federman N, Mascarenhas L, Geoerger B, Dowlati A, Pappo AS, Bielack S, Doz F, McDermott R, Patel JD, Schilder RJ, Tahara M, Pfister SM, Witt O, Ladanyi M, Rudzinski ER, Nanda S, Childs BH, Laetsch TW, Hyman DM, Drilon A. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. *Lancet Oncol* 2020; **21**: 531-540 [PMID: 32105622]

41 **Doebele RC**, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. *Lancet Oncol* 2020; **21**: 271-282 [PMID: 31838007]

42 **Li BT**, Ross DS, Aisner DL, Chaft JE, Hsu M, Kako SL, Kris MG, Varella-Garcia M, Arcila ME. HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers. *J Thorac Oncol* 2016; **11**: 414-419 [PMID: 26723242 DOI: 10.1016/j.jtho.2015.10.025]

43 **Mazières J**, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Felip E, Rouquette I, Milia JD, Gautschi O. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. *J Clin Oncol* 2013; **31**: 1997-2003 [PMID: 23610105 DOI: 10.1200/JCO.2012.45.6095]

44 **Kris MG**, Camidge DR, Giaccone G, Hida T, Li BT, O'Connell J, Taylor I, Zhang H, Arcila ME, Goldberg Z, Jänne PA. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. *Ann Oncol* 2015; **26**: 1421-1427 [PMID: 25899785 DOI: 10.1093/annonc/mdv186]

45 **Mazières J**, Barlesi F, Filleron T, Besse B, Monnet I, Beau-Faller M, Peters S, Dansin E, Früh M, Pless M, Rosell R, Wislez M, Fournel P, Westeel V, Cappuzzo F, Cortot A, Moro-Sibilot D, Milia J, Gautschi O. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. *Ann Oncol* 2016; **27**: 281-286 [PMID: 26598547 DOI: 10.1093/annonc/mdv573]

46 **Li B**, Gandhi L, Besse B, Jhaveri K, Mazières J, Boni V, Shapiro G, Waqar S, Viteri S, Park H, Quinn D, Stemmer S, Cortot A, Burkard M, Scaltriti M, Won H, Lalani A, McCulloch L, Bebchuk J, Xu F, Bryce R, Meric-Bernstam F, Piha-Paul S, Solit D, Janne P. FP14.15 Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies. *J Thorac Oncol* 2021; **16**: S234 [DOI: 10.1016/j.jtho.2021.01.158]

47 **Zhou C**, Li X, Wang Q, Gao G, Zhang Y, Chen J, Shu Y, Hu Y, Fan Y, Fang J, Chen G, Zhao J, He J, Wu F, Zou J, Zhu X, Lin X. Pyrotinib in *HER2*-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study. *J Clin Oncol* 2020; **38**: 2753-2761 [PMID: 32614698 DOI: 10.1200/JCO.20.00297]

48 S**pectrum.** Spectrum Pharmaceuticals Announces Positive Topline Results in HER2 Exon20 Insertion Mutations from Cohort 2 of the Poziotinib ZENITH20 Trial. [Accessed July 28, 2020] Available from: <https://bit.ly/39GKHpp>

49 **Peters S**, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, Baik CS, Isla D, Carpeno JC, Garrido P, Rittmeyer A, Tiseo M, Meyenberg C, de Haas S, Lam LH, Lu MW, Stinchcombe TE. Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. *Clin Cancer Res* 2019; **25**: 64-72 [PMID: 30206164 DOI: 10.1158/1078-0432.CCR-18-1590]

50 **Smit EF**, Nakagawa K, Nagasaka M, Felip E, Goto Y, Li BT, Pacheco JM, Murakami H, Barlesi F, Saltos AN, Perol M, Udagawa H, Saxena K, Shiga R, Guevara FM, Acharyya S, Shahidi J, Planchard D, Janne PA. Trastuzumab Deruxtecan (T-DXd; DS-8201) in Patients with HER2-mutated Metastatic Non–Small Cell Lung Cancer (NSCLC): Interim Results of DESTINY-Lung01. *J Clin Oncol* 2020; **38(15\_suppl)**: 9504 [DOI: 10.1200/JCO.2020.38.15\_suppl.9504]

51 **Ramalingam SS**, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. Overall Survival with Osimertinib in Untreated, *EGFR*-Mutated Advanced NSCLC. *N Engl J Med* 2020; **382**: 41-50 [PMID: 31751012 DOI: 10.1056/NEJMoa1913662]

52 **Nakagawa K**, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2019; **20**: 1655-1669 [PMID: 31591063 DOI: 10.1016/S1470-2045(19)30634-5]

53 **Lamberti G**, Andrini E, Sisi M, Rizzo A, Parisi C, Di Federico A, Gelsomino F, Ardizzoni A. Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma. *Crit Rev Oncol Hematol* 2020; **156**: 103119 [PMID: 33053439 DOI: 0.1016/j.critrevonc.2020.103119]

54 **Canon J**, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, Lanman BA, Werner J, Rapaport AS, San Miguel T, Ortiz R, Osgood T, Sun JR, Zhu X, McCarter JD, Volak LP, Houk BE, Fakih MG, O'Neil BH, Price TJ, Falchook GS, Desai J, Kuo J, Govindan R, Hong DS, Ouyang W, Henary H, Arvedson T, Cee VJ, Lipford JR. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. *Nature* 2019; **575**: 217-223 [PMID: 31666701 DOI: 10.1038/s41586-019-1694-1]

55 **Rolfo C**, Cardona AF, Cristofanilli M, Paz-Ares L, Diaz Mochon JJ, Duran I, Raez LE, Russo A, Lorente JA, Malapelle U, Gil-Bazo I, Jantus-Lewintre E, Pauwels P, Mok T, Serrano MJ; ISLB. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). *Crit Rev Oncol Hematol* 2020; **151**: 102978 [PMID: 32428812 DOI: 10.1016/j.critrevonc.2020.102978]

**Footnotes**

**Conflict-of-interest statement:** Xabier Mielgo-Rubio declares the following conflicts of interest: Advisory role; Boehringer-Ingelheim, AstraZeneca, Bristol Myers Squibb. Speakers’ bureau; Roche, AstraZeneca, Bristol Myers Squibb, MSD, Abbott. Research funding; Bristol Myers Squibb. Luis Cabezón-Gutiérrez received speaker or consulting fees from Angelini, Grunenthal, Kyowa Kirin, Mundipharma, Pfizer, Roche, Rovi, Leo Pharma, Merck Serono, Ipsen Pharma, Lilly, Amgen, Boehringer Ingelheim, and AstraZeneca; The remaining authors declare no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** April 19, 2021

**First decision:** July 6, 2021

**Article in press:**

**Specialty type:** Oncology

**Country/Territory of origin:** Spain

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Zheng G, United States **S-Editor:** Gong ZM **L-Editor:** A **P-Editor:** Gong ZM

**Table 1 Phase II trials with BRAF inhibitors**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Drug** | ***n*** | **ORR (%)** | **PFS (mo)** | **OS (mo)** |
| Vemurafenib BRAF V600E[8] | 62 | 37.1 | 6.51 | 15.38 |
| Vemurafenib V600E[9] | 101 | 0 | 5.2 | 10 |
| Vemurafenib non-V600E[9] | 17 | 44.9 | NR | NR |
| Dabrafenib in 2nd line or beyond[10] | 78 | 33.3 | 5.5 | 12.7 |
| Dabrafenib + trametinib in 2nd line or beyond[11] | 57 | 63.2 | 10.2 | 18.2 |
| Dabrafenib + trametinib en 1st line[12] | 36 | 64 | 10.9 | 24.6 |

ORR: Overall response rate; PFS: Progression free survival; OS: Overall survival; NR: Not reported.

**Table 2 Phase II trials with multikinase RET inhibitors**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Drug** | ***n*** | **ORR** | **PFS** | **OS** |
| Cabozantinib[22] | 25 | 28% | 5.5 mo | 9.9 mo |
| Vandetanib[23] | 18 | 18% | 4.5 mo | 11.6 mo |
| Lenvatinib[24] | 25 | 16% | 7.3 mo | NR |
| Sorafenib[25] | 3 | 0 | NR | NR |
| Selpercatinib[26] | 105 | 64% in platinum chemotherapy pretreated | 90% in response at 6 mo | NR |
| 85% in platinum chemotherapy naïve |
| Pralsetinib[27] | 106 | 61% in platinum chemotherapy pretreated | NR | NR |
| 73% in platinum chemotherapy naïve |

ORR: Overall response rate; PFS: Progression free survival; OS: Overall survival; NR: Not reported.

**Table 3** **Mesenchymal-epithelial transition factor inhibitors**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Drug** | **MET-specific** | **Type** | **Other targets** | **IC50 (nmol/L)** |
| Crizotinib | No | Ia | ALK, ROS1 | 22.5 |
| Capmatinib | Yes | Ib | -- | 0.6 |
| Tepotinib | Yes | Ib | -- | 3 |
| Salovitinib | Yes | Ib | -- | 2.1 |
| Bozitinib | Yes | I | -- | 0.51 |
| Cabozantinib | No | II | RET, ROS1, VEGFR2, KIT | 7.8 |
| Merestinib | No | II | TIE-1, AXL, ROS1, DDR1/2, FLT3, MERTK, RON | 8.1 |
| Glesatinib | No | II | MET, VEGFR, RON, TIE-2 | 21.1 |

IC50: Half maximal inhibitory concentration; MET: Mesenchymal-epithelial transition factor.

**Table 4 Clinical trials of mesenchymal-epithelial transition factor inhibitors**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Drug** | **Clinical trial** | **Phase** | **Treatment** | **Objective** | **Status** |
| Glesatinib | NCT02954991 | 2 | Glesatinib + Nivolumab | ORR | Active, not recruiting |
| Multi-TKI |
| Glesatinib | NCT02544633 | 2 | Glesatinib | ORR | Completed |
| Multi-TKI |
| Merestinib | NCT02920996 | 2 | Merestinib | ORR | Active, not recruiting |
| Multi-TKI |
| Savolitinib | NCT02897479 | 2 | Savolitinib | ORR | Active, not recruiting |
| Selective-TKI |
| Telisotuzumab (ABBV 399) | NCT03574753 | 2 | ABBV-399 | ORR | Completed |
| MET-mab |
| JNJ-61186372 | NCT02609776 | 1 | JNJ-61186372 | ORR, security | Recruiting |
| EGFR and MET mab |

TKI: Tyrosine kinase inhibitor; mab: Monoclonal antibody; ORR: Overall response rate; MET: Mesenchymal-epithelial transition factor; EGFR: Epidermal growth factor receptor.

**Table 5 Phase II trials with HER2 inhibitors**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Drug** | **Molecular alteration** | ***n*** | **ORR%** | **PFS (mo)** | **OS (mo)** |
| Dacomitinib[44] | HER2 mutant | 26 | 12 | NR | NR |
| HER2-amplified | 4 | 0 | NR | NR |
| Neratinib + Trastuzumab[46] | HER2 mutant | 52 | 17 | 4 | 10.2 |
| Neratinib + Temsirolimus[46] | HER2 mutant | 43 | 19 | 4 | 15.1 |
| Pyrotinib[47] | HER2 mutant | 60 | 30 | 6.9 | 14.4 |
| Poziotinib[48] | HER2 mutant | 90 | 28 | 5.5 | NR |
| Trastuzumab emtansine[49] | IHC 2+ | 29 | 0 | 2.6 | 12.2 |
| IHC 3+ | 20 | 20 | 2.7 | 15.3 |
| Trastuzumab deruxtecan[49] | HER-2 mutant | 42 | 61.9 | NR | NR |
| Trastuzumab deruxtecan[49] | IHC 2+ | 39 | 25.6 | 5.4 | 11.3 |
| IHC 3+ | 10 | 20 |

ORR: Overall response rate; PFS: Progression free survival; OS: Overall survival; NR: Not reported.